cd20bi-aatc
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00521261)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd20bi-aatc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00938626 | Phase 1 | Oct 1, 2009 | National Cancer Institute (NCI), Wayne State University |
| NCT00521261 | Phase 1 | Oct 1, 2007 | National Cancer Institute (NCI), Wayne State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2007 |
| Wayne State University | Academic/Hospital | 2 | 2 | 1 | 2007 |
2 organizations
Page 1 / 1